title: Inhibition of ATP synthase by chlorinated adenosine analogue.
abstract: 8-Chloroadenosine (8-Cl-Ado) is a ribonucleoside analogue that is currently in clinical trial for chronic lymphocytic leukemia. Based on the decline in cellular ATP pool following 8-Cl-Ado treatment, we hypothesized that 8-Cl-ADP and 8-Cl-ATP may interfere with ATP synthase, a key enzyme in ATP production. Mitochondrial ATP synthase is composed of two major parts; F(O) intermembrane base and F1 domain, containing alpha and beta subunits. Crystal structures of both alpha and beta subunits that bind to the substrate, ADP, are known in tight binding (alpha(dp)beta(dp)) and loose binding (alpha(tp)beta(tp)) states. Molecular docking demonstrated that 8-Cl-ADP/8-Cl-ATP occupied similar binding modes as ADP/ATP in the tight and loose binding sites of ATP synthase, respectively, suggesting that the chlorinated nucleotide metabolites may be functional substrates and inhibitors of the enzyme. The computational predictions were consistent with our whole cell biochemical results. Oligomycin, an established pharmacological inhibitor of ATP synthase, decreased both ATP and 8-Cl-ATP formation from exogenous substrates, however, did not affect pyrimidine nucleoside analogue triphosphate accumulation. Synthesis of ATP from ADP was inhibited in cells loaded with 8-Cl-ATP. These biochemical studies are in consent with the computational modeling; in the alpha(tp)beta(tp) state 8-Cl-ATP occupies similar binding as ANP, a non-hydrolyzable ATP mimic that is a known inhibitor. Similarly, in the substrate binding site (alpha(dp)beta(dp)) 8-Cl-ATP occupies a similar position as ATP mimic ADP-BeF(3)(-). Collectively, our current work suggests that 8-Cl-ADP may serve as a substrate and the 8-Cl-ATP may be an inhibitor of ATP synthase.
authors.affiliation: Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Lisa S
authors.initials: LS
authors.lastname: Chen
authors.forename: Billie J
authors.initials: BJ
authors.lastname: Nowak
authors.forename: Mary L
authors.initials: ML
authors.lastname: Ayres
authors.forename: Nancy L
authors.initials: NL
authors.lastname: Krett
authors.forename: Steven T
authors.initials: ST
authors.lastname: Rosen
authors.forename: Shuxing
authors.initials: S
authors.lastname: Zhang
authors.forename: Varsha
authors.initials: V
authors.lastname: Gandhi
mesh_terms: D015762:2-Chloroadenosine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D025181:ATP Synthetase Complexes / Q000737:chemistry / Q000187:drug effects*; D000241:Adenosine / Q000737:chemistry / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology; D006019:Glycolysis / Q000187:drug effects / Q000502:physiology; D054879:Halogenation; D006868:Hydrolysis; D008958:Models, Molecular; D010101:Oxygen Consumption / Q000187:drug effects; D011485:Protein Binding; D011487:Protein Conformation / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D015762:2-Chloroadenosine; D025181:ATP Synthetase Complexes; D000241:Adenosine; C075440:8-chloroadenosine